Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779296 | 0.82 | DUT (0.35) | NOS2KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL17471300 | 0.75 | NOS2 (0.40) | NOS2KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL590534 | 0.74 | AKT1 (0.36) | NOS2LMNAAPEX1PMP22 | |
| SCHEMBL906834 | 0.73 | IDO1 (0.48) | LMNABACE1 | |
| SCHEMBL3135931 | 0.71 | — | — | |
| SCHEMBL1315036 | 0.71 | IDO1 (0.46) | LMNABACE1 | |
| SCHEMBL18839725 | 0.70 | KDM4E (0.33) | DUT | |
| SCHEMBL19219151 | 0.70 | LMNA (0.31) | LMNA | |
| SCHEMBL4762505 | 0.70 | NOS2 (0.42) | NOS2KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL15489965 | 0.69 | TDP1 (0.37) | BACE1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025111492-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4526304-A1 | INHIBITORS OF PARG | 858 Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-10722520-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2020-07-28 | — | — | US | disclosed |
| US-10722520-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190224210-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-07-25 | — | — | US | disclosed |
| US-20190224210-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-07-25 | — | — | US | disclosed |
| WO-2018060481-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-04-05 | — | — | WO | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | PARG, PLG, PTGIS | NOS2 1281/4885KCNH2 2538/4885LMNA 354/4885 |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | NOS2 1828/4885KCNH2 1359/4885LMNA 2803/4885 |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | NOS2 2016/4885KCNH2 2332/4885LMNA 1995/4885 |
| US-10722520-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | GNE, CFTR, FPR1 | NOS2 1611/4885KCNH2 2949/4885LMNA 3088/4885 |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | PARG, PLG, PARN | NOS2 2975/4885KCNH2 3452/4885LMNA 474/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | NOS2 2023/4885KCNH2 936/4885LMNA 2505/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | NOS2 2237/4885KCNH2 2834/4885LMNA 574/4885 |
| US-20190224210-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | GNE, CFTR, FPR1 | NOS2 1611/4885KCNH2 2949/4885LMNA 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.